Foghorn Therapeutics Profit Margin

Foghorn Therapeutics (FHTX) currently reports a profit margin of -175.78% as of June 2026. That compares with -311.9% in the prior-year period — up 43.6% year over year. That is below the Healthcare sector average of 13.76%. Use the charts on this page to explore Foghorn Therapeutics's profit margin history and peer comparisons.

Foghorn Therapeutics's profit margin increased from -311.9% to -175.78% — a 43.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Foghorn Therapeutics's profit margin of -175.78% is lower than the Healthcare sector average of 13.76%. That is roughly 1377.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Foghorn Therapeutics's current -175.78% should be judged against Healthcare norms (sector average: 13.76%) and against FHTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -175.78%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.76%. From there, open related valuation or income-statement pages for Foghorn Therapeutics, and consider following FHTX for alerts when major investors trade the stock.